Combined OC (Levonorgestrel / Ethinyl Estradiol)

Hormonal Contraceptiveprescriptionoral · inferred

Combined oral contraceptive containing levonorgestrel (progestin, t1/2 ~24h) and ethinyl estradiol (estrogen, t1/2 ~12h). Brands: Alesse, Levlen, Seasonique. Steady state in ~7 days. Take at same time daily.

Projected serum levels — 1 pill (≈ 0.17 mg), once daily

Combined OC (Levonorgestrel / Ethinyl Estradiol)
Combined OC (Levonorgestrel / Ethinyl Estradiol) modeled serum levels, 1 pill (≈ 0.17 mg) once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 pill (≈ 0.17 mg) once daily (oral).

Modeled steady state after ~1 days: peak ≈ 0.064 mg, trough ≈ 0.003 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Hormonal Contraceptive
Route modeled
Oral
Model confidence
inferred
Half-life
4.9 h
Common dose
1 pill (≈ 0.17 mg)
Suggested maximum
1 pill/day
Reference dose range
0.50–1 pill (single dose)
Suggested cadence
once daily

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Combined OC (Levonorgestrel / Ethinyl Estradiol) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Combined OC (Levonorgestrel / Ethinyl Estradiol) AUC by ~0.31x

  • danger
    Combined OC (Norgestimate / Ethinyl Estradiol) + Combined OC (Levonorgestrel / Ethinyl Estradiol) Stacked effects

    Combined OC (Levonorgestrel / Ethinyl Estradiol) and Combined OC (Norgestimate / Ethinyl Estradiol) both push the androgen receptor, estrogen receptor alpha, and progesterone receptor in the same…

  • danger
    Efavirenz (Sustiva) + Combined OC (Levonorgestrel / Ethinyl Estradiol) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Combined OC (Levonorgestrel / Ethinyl Estradiol) AUC by ~0.21x

  • danger
    Nicotine + Combined OC (Levonorgestrel / Ethinyl Estradiol) Contraindicated

    Smoking while on combined OCs dramatically increases risk of blood clots, stroke, and heart attack. Risk increases with age (especially >35).

  • danger
    Norgestimate + Combined OC (Levonorgestrel / Ethinyl Estradiol) Stacked effects

    Combined OC (Levonorgestrel / Ethinyl Estradiol) and Norgestimate both push the androgen receptor, estrogen receptor alpha, and progesterone receptor in the same direction.

  • danger
    NuvaRing (Etonogestrel / EE Vaginal Ring) + Combined OC (Levonorgestrel / Ethinyl Estradiol) Stacked effects

    Combined OC (Levonorgestrel / Ethinyl Estradiol) and NuvaRing (Etonogestrel / EE Vaginal Ring) both push the androgen receptor, estrogen receptor alpha, and progesterone receptor in the same…

Serum checks 138 modeled interaction pairings for combined oc (levonorgestrel / ethinyl estradiol) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics of Single and Multiple Doses of Ethinyl Estradiol and Levonorgestrel in Relation to Smoking Crawford FE et al. · Clinical Pharmacology & Therapeutics, 1988 DOI

    Characterized EE and LNG pharmacokinetics showing smoking increases EE clearance by 50%, potentially reducing contraceptive efficacy in smokers.

  2. Pharmacokinetics of Levonorgestrel and Ethinylestradiol in 9 Women Who Received a Low-Dose Oral Contraceptive Kuhnz W et al. · Contraception, 1992 DOI

    Three-month PK study showing levonorgestrel accumulates at steady state with elimination half-life increasing from 20h to 24-26h with chronic dosing.

  3. New Low-Dose Extended-Cycle Pills with Levonorgestrel and Ethinyl Estradiol: An Evolutionary Step in Birth Control Nelson AL · International Journal of Women's Health, 2010 DOI

    Review of extended-cycle OC formulations pharmacology including continuous hormone exposure benefits and reduced hormone-free interval bleeding.

3 published studies referenced in the app, each with a plain-language summary.